The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.
David S. Hong
Research Funding - ISIS
Anas Younes
Consultant or Advisory Role - ISIS
Luis Fayad
No relevant relationships to disclose
Nathan Hale Fowler
No relevant relationships to disclose
Fredrick B. Hagemeister
No relevant relationships to disclose
Reena Mistry
Research Funding - ISIS
John J. Nemunaitis
Research Funding - ISIS
Mitesh J. Borad
Research Funding - ISIS
Alan H. Bryce
Consultant or Advisory Role - ISIS
Mason Yamashita
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Steven George Hughes
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Theodore Jesse Kwoh
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
A. Robert MacLeod
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Dan Norris
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Ron Baldwin
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Gene Hung
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Brett P. Monia
Employment or Leadership Position - ISIS
Stock Ownership - ISIS
Razelle Kurzrock
Research Funding - ISIS